Objective:

The article examines the objective, findings, and clinical context described in CDC flags neuro symptoms after unapproved botulinum toxin.

Approach:

• Investigation: Public health authorities reviewed the spa’s injection practices, products, and patient outcomes and surveyed 52 patients treated from December 2025 through January 2026; 27 responded.
• Product testing: The implicated lot was unavailable for testing. CDC tested a different lot collected at the spa.

Key Findings:

• Three women reported neurologic symptoms after receiving the same unapproved product from the same lot. Symptoms included combinations of numbness or tingling, weakness, breathing difficulty, neck stiffness, dysphonia, headache, and blurred vision.
• All three women recovered without hospitalization; one sought outpatient medical care.
• Testing of a different lot detected active botulinum neurotoxin type A but found no elevated toxin levels or contaminants.
• Inspectors identified violations involving product sourcing, diluent, multi-patient use of single-dose vials, temperature monitoring, and storage or use of reconstituted, unlabeled products past their beyond-use dates.

Interpretation:

The investigation did not determine whether product concentration, contamination, or improper preparation, administration, or storage contributed to the symptoms.

Limitations:

• The implicated product lot was unavailable for testing.
• Only 27 of 52 surveyed patients responded.

Conclusion:

Authorities ordered the provider to stop using unapproved products and filed a formal complaint with Colorado regulators. The provider later reported discontinuing their use. CDC advised reporting adverse events through FDA MedWatch and cautioned providers against purchasing or administering unapproved products from unauthorized suppliers.

Sources:

• CDC, Morbidity and Mortality Weekly Report